15-Year Check-In: how safe is this CAR T-Cell therapy?
Knowledge-focused
Not yet recruiting
This study follows 18 people who already received GF-CART01, a type of cell therapy for certain blood cancers like lymphoma. Researchers will monitor participants for up to 15 years to see if any serious side effects occur and how long the modified cells stay in the body. The goa…
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC